Adolescent providers’ knowledge of human papillomavirus vaccination age guidelines in five countries

References

• 2006 approval letter - human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant. Rockville (MD): Department of Health and Human Services; 2006.
   Google Scholar
• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670. doi:10.1002/ijc.30716.
   PubMed Web of Science ®Google Scholar
• Hartwig S, St Guily JL, Dominiak-Felden G, Alemany L, de Sanjosé S. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer. 2017;12(1):19. doi:10.1186/s13027-017-0129-6.
   PubMed Web of Science ®Google Scholar
• Castle PE, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W. Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol. 2009;114(2):365–369. doi:10.1016/j.ygyno.2009.04.035.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R. Human papillomavirus vaccine should be given before sexual debut for maximum benefit. J Infect Dis. 2007;196(10):1431–1432. doi:10.1086/522869.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241–268.
   PubMedGoogle Scholar
• Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36(32Pt A):4761–4767. doi:10.1016/j.vaccine.2018.02.003.
   PubMed Web of Science ®Google Scholar
• Smith JC, Snider DE, Pickering LK. Immunization policy development in the United States: the role of the advisory committee on immunization practices. Ann Intern Med. 2009;150(1):45–49. doi:10.7326/0003-4819-150-1-200901060-00009.
   PubMed Web of Science ®Google Scholar
• Pickering LK, Orenstein WA. Development of pediatric vaccine recommendations and policies. Semin Pediatr Infect Dis. 2002;13(3):148–154. doi:10.1053/spid.2002.125857.
   PubMedGoogle Scholar
• Gamble HL, Klosky JL, Parra GR, Randolph ME. Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol. 2010;35(7):704–715. doi:10.1093/jpepsy/jsp108.
   PubMed Web of Science ®Google Scholar
• Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US national immunization survey. Am J Public Health. 2013;103(1):164–169. doi:10.2105/AJPH.2011.300600.
   PubMed Web of Science ®Google Scholar
• Vielot NA, Goldberg SK, Zimet G, Smith SB, McDonald MA, Ramos S, Morgan K, Joo Kim C, Richter KL, Peris M, et al. Acceptability of multipurpose human papillomavirus vaccines among providers and mothers of adolescent girls: A mixed-methods study in five countries. Papillomavirus Res. 2017;3:126–133. doi:10.1016/j.pvr.2017.04.001.
   PubMed Web of Science ®Google Scholar
• Islam JY, Hoyt AM, Ramos S, Morgan K, Kim CJ, de Sanjose S, Butera N, Senkomago V, Richter KL, McDonald MA, et al. Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries. Cancer Causes Control. 2018;29:1115–1130. doi:10.1007/s10552-018-1085-1.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Clark JA. What affects human papillomavirus vaccination rates? A qualitative analysis of providers’ perceptions. Women’s Heal Issues. 2012;22(4):e379–e386. doi:10.1016/j.whi.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Stahlman S, Walker S, Gottlieb S, Markowitz L, Liddon N, Plant A, Guerry S. Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community. Vaccine. 2012;30:4511–4516. doi:10.1016/j.vaccine.2012.04.062.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the advisory committee on immunization practices. Morb Mortal Wkly Rep. 2016;65(49):1405–1408. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec. 2014;89(21):221–236.
   PubMedGoogle Scholar
• Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, Nene BM, Esmy PO, Joshi S, Poli URR, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2016;17(1):67–77. doi:10.1016/S1470-2045(15)00414-3.
   PubMed Web of Science ®Google Scholar
• Iversen O-E, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Nur Azurah AG, Fong SM, et al. Immunogenicity of the 9-valent HPV vaccine using 2-Dose regimens in girls and boys vs a 3-Dose regimen in women. JAMA. 2016;316(22):2411. doi:10.1001/jama.2016.17615.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta‐analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–1799. doi:10.1086/657321.
   PubMed Web of Science ®Google Scholar
• Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Heal. 2008;43(4):S5.e1-S5.e62. doi:10.1016/j.jadohealth.2008.07.009.
   Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40(6):564–571. doi:10.1016/j.jadohealth.2007.02.015.
   PubMed Web of Science ®Google Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KED, Marchant CD, Castellsague X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135–2145. doi:10.1542/peds.2006-0461.
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11(1):227. doi:10.1186/1741-7015-11-227.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244–251. doi:10.3201/eid1402.070499.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151(8):538–545. doi:10.7326/0003-4819-151-8-200910200-00007.
   PubMed Web of Science ®Google Scholar
• Warner EL, Ding Q, Pappas L, Bodson J, Fowler B, Mooney R, Kirchhoff AC, Kepka D. Health care providers’ knowledge of HPV vaccination, barriers, and strategies in a state with low HPV vaccine receipt: mixed-methods study. JMIR Cancer. 2017;3(2):e12. doi:10.2196/cancer.7345.
   PubMed Web of Science ®Google Scholar
• Henrikson NB, Tuzzio L, Gilkey MB, McRee A-L. “You’re never really off time”: healthcare providers’ interpretations of optimal timing for HPV vaccination. Prev Med Reports. 2016;4:94–97. doi:10.1016/J.PMEDR.2016.05.002.
   PubMedGoogle Scholar
• Kulczycki A, Qu H, Shewchuk R. Primary care physicians’ adherence to guidelines and their likelihood to prescribe the human papillomavirus vaccine for 11- and 12-year-old girls. Women’s Hea Issues. 2016;26(1):34–39. doi:10.1016/j.whi.2015.07.012.
   PubMed Web of Science ®Google Scholar
• Bruno DM, Wilson TE, Gany F, Aragones A. Identifying human papillomavirus vaccination practices among primary care providers of minority, low-income and immigrant patient populations. Vaccine. 2014;32(33):4149–4154. doi:10.1016/j.vaccine.2014.05.058.
   PubMed Web of Science ®Google Scholar
• Hswen Y, Gilkey MB, Rimer BK, Brewer NT. Improving physician recommendations for human papillomavirus vaccination: the role of professional organizations. Sex Transm Dis. 2017;44(1):42–47. doi:10.1097/OLQ.0000000000000543.
   PubMed Web of Science ®Google Scholar
• Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer. A report to the president of the United States from the president’s cancer panel. Bethesda (MD): National Cancer Institute; 2014.
   Google Scholar
• Cervical Cancer Vaccine Card News. Korea centers for disease control & prevention. 2016. [ accessed 2018 Nov 19]. https://nip.cdc.go.kr/irgd/manage.do?service=getAcbbsView&BBSSEQNUM=98&GRPID=nip&BRDCOD=form.
   Google Scholar
• AFIX (Assessment, Feedback, Incentives, and eXchange). [ accessed 2018 Oct 31]. https://www.cdc.gov/vaccines/programs/afix/index.html
   Google Scholar
• Gilkey MB, Dayton AM, Moss JL, Sparks AC, Grimshaw AH, Bowling JM, Brewer NT. Increasing provision of adolescent vaccines in primary care: a randomized controlled trial. Pediatrics. 2014;134(2):e346–53. doi:10.1542/peds.2013-4257.
   PubMed Web of Science ®Google Scholar
• Berkowitz Z, Malone M, Rodriguez J, Saraiya M. Providers’ beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: findings from a provider survey, 2012. Prev Med (Baltim). 2015;81:405–411. doi:10.1016/j.ypmed.2015.10.007.
   Web of Science ®Google Scholar